Rakovina Therapeutics Inc Cash Flow-to-Debt Ratio
Rakovina Therapeutics Inc cash flow-to-debt ratio. Rakovina Therapeutics Inc (RKV) has a Cash Flow-to-Debt Ratio of -0.31x as of September 2025, meaning its operating cash flow of CA$-1.04 Million could theoretically repay 0% of its total liabilities (CA$3.38 Million) in one year. See Rakovina Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Rakovina Therapeutics Inc (2021–2024)
Cash flow-to-debt ratio of Rakovina Therapeutics Inc from 2021 to 2024. Historical debt coverage capacity for Rakovina Therapeutics Inc across 4 annual periods. Also explore Rakovina Therapeutics Inc (RKV) equity growth momentum to track the company's year-over-year net asset growth rate.
Rakovina Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2021–2024)
Rakovina Therapeutics Inc cash flow-to-debt ratio by year from 2021 to 2024. Year-by-year debt coverage analysis for Rakovina Therapeutics Inc. For the full cash flow conversion analysis, see RKV cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.99x | CA$-3.86 Million | CA$1.94 Million | ▼ -58.6% |
| 2023 | -1.25x | CA$-1.86 Million | CA$1.49 Million | ▲ +93.0% |
| 2022 | -17.91x | CA$-1.92 Million | CA$107.05K | ▲ +11.6% |
| 2021 | -20.25x | CA$-2.31 Million | CA$113.98K | — |